SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease

Background: Urinary symptoms are common, disabling and generally unresponsive to treatment in Parkinson´s disease (PD). Safinamide is approved as an add-on therapy to levodopa to improve fluctuations. Methods: Retrospective analysis of electronic records of nondemented PD patients seen consecutively...

Full description

Bibliographic Details
Published in:	Brain Sciences
Main Authors:	Ana Gómez-López, Arantxa Sánchez-Sánchez, Elena Natera-Villalba, Victoria Ros-Castelló, Álvaro Beltrán-Corbellini, Samira Fanjul-Arbós, Isabel Pareés Moreno, José Luis López-Sendon Moreno, Juan Carlos Martínez Castrillo, Araceli Alonso-Canovas
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Subjects:	safinamide urinary symptoms Parkinson disease nonmotor fluctuations
Online Access:	https://www.mdpi.com/2076-3425/11/1/57

Similar Items

Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus
by: Ana Margarida Rodrigues, et al.
Published: (2025-01-01)

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
by: Javier Pagonabarraga, et al.
Published: (2020-03-01)

Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review
by: Pilar Sanchez Alonso, et al.
Published: (2023-02-01)

Respiratory alkalosis as an adverse effect of safinamide?
by: Flávia Freitas, et al.
Published: (2024-10-01)

Use of safinamide for treatment of Parkinson disease: real-world data from Spain
by: María Isabel Morales Casado, et al.
Published: (2025-07-01)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
by: Stocchi F, et al.
Published: (2016-02-01)

Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
by: Esteban Peña, et al.
Published: (2021-02-01)

Enhancing the Solubility and Dissolution Performance of Safinamide Using Salts
by: Lei Gao, et al.
Published: (2020-10-01)

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study
by: Roongroj Bhidayasiri, et al.
Published: (2023-03-01)

Establishment of a sensitive UPLC-MS/MS method to quantify safinamide in rat plasma
by: Ying Wang, et al.
Published: (2023-08-01)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
by: Espinoza-Vinces C, et al.
Published: (2023-10-01)

Evaluation of developmental toxicity of safinamide in zebrafish larvae (Danio rerio)
by: Zhengkang Su, et al.
Published: (2023-09-01)

Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review
by: Antonio J Garcia Ruiz, et al.
Published: (2025-08-01)

Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice
by: P. Pérez-Torre, et al.
Published: (2024-05-01)

Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
by: Diego Santos García, et al.
Published: (2021-03-01)

Long-Term Real-World Experience with Safinamide in Patients with Parkinson’s Disease
by: Anna Planas-Ballvé, et al.
Published: (2024-12-01)

Stability-indicating spectrophotometric quantification of safinamide in the presence of its possible degradation product
by: Ebraam B. Kamel, et al.
Published: (2025-01-01)

Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson’s Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose
by: Ángela Solleiro Vidal, et al.
Published: (2025-06-01)

Application of a Quality by Design Approach to Develop a Simple, Fast, and Sensitive UPLC-MS/MS Method for Quantification of Safinamide, an Antiparkinson’s Drug, in Plasma
by: Essam A. Ali, et al.
Published: (2023-08-01)

Comparing the efficacy and safety of safinamide with rasagiline in China Parkinson’s disease patients with a matching adjusted indirect comparison
by: Yuyan Tan, et al.
Published: (2025-03-01)

Safinamide as an adjunct to levodopa monotherapy in Asian patients with Parkinson’s disease experiencing early wearing-off: a pooled analysis of the J-SILVER and KEEP studies
by: Noriko Nishikawa, et al.
Published: (2025-06-01)

Ecofriendly micellar mediated spectrofluorimetric method for ultrasensitive quantification of the antiparkinsonian drug safinamide in pharmaceutical formulation and spiked human plasma
by: Engy A. Ibrahim, et al.
Published: (2024-07-01)

A novel stability-indicating chromatographic quantification of the antiparkinsonian drug safinamide in its pharmaceutical formulation employing HPTLC densitometry and ion-pair HPLC–DAD
by: Engy A. Ibrahim, et al.
Published: (2024-11-01)

Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease
by: Panteleimon Oikonomou, et al.
Published: (2021-05-01)

Incapacitating pain in Parkinson’s disease: A case report
by: Agam Jain, et al.
Published: (2024-05-01)

FOCAL DYSTONIAS: NON-MOTOR SYMPTOMS AND COMORBIDITIES
by: V. A. Tolmachyova
Published: (2017-05-01)

Depression is associated with the nonmotor symptoms of Parkinson's disease: A comparative analysis
by: Mahsa Mayeli, et al.
Published: (2024-05-01)

Depression in Parkinson’s Disease – Profile and Assessment
by: Desislava Marinova, et al.
Published: (2023-12-01)

Is gut microbiota associated with Parkinson’s disease?
by: A. V. Tyakht, et al.
Published: (2017-01-01)

A Selective, Efficient, Facile, and Reusable Natural Clay/Metal Organic Framework as a Promising Adsorbent for the Removal of Drug Residue and Heavy Metal Ions
by: Rania Abdelazeem, et al.
Published: (2024-09-01)

Exploring walkability patterns in diverse urban landscapes: A comprehensive spatial geographic analysis of a megacity in Thailand
by: Pawinee Iamtrakul, et al.
Published: (2025-09-01)

A User-Friendly Nonmotorized Device for Ankle Rehabilitation
by: Rogério Sales Gonçalves, et al.
Published: (2023-02-01)

Sleep and other non-motor symptoms in patients with idiopathic oromandibular dystonia and meige syndrome: A questionnaire-based study
by: Somdattaa Ray, et al.
Published: (2021-01-01)

Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests
by: Mubasher A. Qamar, et al.
Published: (2023-05-01)

Identification of wearing-off manifestations (reduction of levodopa effect) in Parkinson's disease using specific questionnaire and comparison of the results with routine ambulatory evaluations Identificação de manifestações de wearing-off (redução do efeito da levodopa) em pacientes com doença de Parkinson utilizando questionário específico e comparação dos resultados com avaliações ambulatoriais de rotina
by: Luciano Magalhães Melo, et al.
Published: (2010-08-01)

Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
by: Gustav Cedergren Weber, et al.
Published: (2023-08-01)

Impact of Depression and Anxiety on Dimensions of Health-Related Quality of Life in Subjects with Parkinson’s Disease Enrolled in an Association of Patients
by: Fany Chuquilín-Arista, et al.
Published: (2021-06-01)

Flecainide mediated sodium channel blockade enhances blood brain barrier integrity and promotes neuroprotection in neuroinflammation
by: Mustafa Sindi, et al.
Published: (2025-08-01)

Nonmotor Symptoms Differ Between Essential Tremor and Tremor‐Dominant Parkinson's Disease
by: Mingqiang Li, et al.
Published: (2025-02-01)

Nonmotor symptoms in Parkinson’s disease patients in South Asia: A systematic review and meta-analysis
by: Prayash Paudel, et al.
Published: (2025-01-01)